The efficacy of BIIBO59 in patients with cutaneous lupus erythematosus with and without concomitant systemic lupus erythematosus during 16 weeks was evaluated.
The association between HS and strokes was assessed via a systematic review and meta-analysis.
The safety and efficacy of ruxolitinib cream following 104 weeks of treatment in a phase 2 study of adults is reported.
At AAD VMX 2021, researchers presented data on skin clearance rates through 5 years with guselkumab in patients with moderate to severe plaque psoriasis.
Determining if treatment with tralokinumab would lead to long-term improvements in symptoms related to atopic dermatitis was the goal of this study.
The effect of repeated DAXI treatment on static glabellar line severity was evaluated.
The prevalence and association of metabolic syndrome in patients with vitiligo was determined via analyses in this study.
The effect of ligelizumab on sleep in patients with chronic spontaneous urticaria who had been treated with omalizumab is explored.
Analyses demonstrated improvement in key treatment outcomes vs placebo associated with baricitinib for the treatment of atopic dermatitis.
Baseline characteristics and treatment outcomes of patients with early-onset and late-onset alopecia areata are evaluated.
Researchers assessed the effects of BMI on topical acne treatments in younger patients.
The investigators reported efficacy results from the MAXIMISE trial, the first randomized controlled trial evaluating the efficacy of a biologic agent in the treatment of axial manifestations in PsA.
A study shows 7.8% of patients with psoriasis who were treated with methotrexate developed nonmelanoma skin cancer.
The comparative efficacy of biologic agents and oral therapies for plaque psoriasis was evaluated.
The efficacy and safety of systemic treatments for moderate to severe atopic dermatitis in monotherapy and combination therapy was investigated.
Pooled data analyses on efficacy, safety, and 1-year follow-up on the use of tirbanibulin for the treatment of actinic keratosis lesions was presented at the AAD VMX 2021.
The safety, tolerability, and efficacy of sofpironium bromide gel for the treatment of primary axillary hyperhidrosis was evaluated.
The influence of Vichy volcanic mineralizing water and hyaluronic acid treatment on rosacea was presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2021.
The latest data on the safety and efficacy of roflumilast foam for scalp and body psoriasis was presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2021.
The efficacy of topical acne treatments is not affected by body mass index (BMI).
Researchers compared the safety and efficacy of treatment with deucravacitinib vs placebo and apremilast in patients with moderate to severe plaque psoriasis.
Researchers sought to determine whether there were any clinically meaningful improvements in AD signs, symptoms, and quality of life in pediatric patients treated with different doses of dupilumab.
Study researchers presented their findings at AAD 2021 on the relationship between statin therapy and risk for squamous cell carcinoma tumors in men.
Researchers at the AAD vmx 2021 describe the efficacy of ruxolitinib cream for atopic dermatitis based on baseline clinical characteristics using data from 2 studies.